In a study newly published in the medical journal Clinical Toxicology, “therapeutic misuse” of OTC combination products containing acetaminophen was infrequent and declined over a 10-year period.
The proper application/usage, scope, and cause for revisions of the <661> suite of chapters is not clear nor intuitive which is a concern given the potential impact.
The dietary supplement industry’s self-regulatory coalition, the SIDI Work Group, today released an updated version of the Standardized Information on Dietary Ingredients (SIDI TM) Protocol.
CHPA applauds Colorado for enacting a law prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors this week.
CHPA applauds the House of Representatives’ passage of legislation that will restore consumers’ ability to use their HSAs and FSAs to purchase over-the-counter medicines and feminine hygiene products.
CHPA is pleased to see FDA’s long-awaited draft guidance on innovative approaches for greater consumer access to nonprescription medicines, and applauds FDA’s focus on patient safety as a top priority.
Millions of American families rely on FSAs, HSAs, and other tax-preferred accounts to help meet their basic healthcare needs, including the purchase of OTC medicines.
CHPA applauds New Hampshire for becoming the 35th state to adopt the real-time, stop-sale technology called the National Precursor Log Exchange (NPLEx), a system used by retailers across the country to help prevent the illegal sale of pseudoephedrine.
Restricting consumers’ ability to utilize their own FSAs and HSAs and other tax-preferred accounts impose an unfair cost increase on individuals and families at a time when many are struggling financially.
CHPA applauds the U.S. House Ways and Means Health Subcommittee for today’s hearing, examining the benefits of consumer access to tax-preferred savings accounts, HSAs and FSAs.
